- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer CenterNCI CANCERLIT® Search: Islet Cell Carcinoma - April 2002
National Cancer Institute®
Last Modified: April 1, 2002
Table of Contents
1
UI - 11833554
AU - Hui AC; Ozaki R; Kay R; Cockram CC
TI -
Seizure recurrence in temporal lobe epilepsy.
SO - Int J Clin Pract 2002 Jan-Feb;56(1):63-4
AD - Department of Medicine and Therapeutics, Prince of Wales Hospital, Hong
Kong, Shatin, NT, China.
We report on a patient with clinical, electroencephalographic and
radiological features of temporal lobe epilepsy, whose seizures were
initially controlled with antiepileptic treatment. Five years after the
onset of seizures, he developed more frequent and prolonged episodes of
confusion, which were misinterpreted as secondary to temporal lobe
epilepsy. Further investigation revealed the presence of hypoglycaemia
and the eventual diagnosis of metastatic insulinoma.
2
UI - 11900219
AU - Shojamanesh H; Gibril F; Louie A; Ojeaburu JV; Bashir S; Abou-Saif A;
TI -
Jensen RT
Prospective study of the antitumor efficacy of long-term octreotide
treatment in patients with progressive metastatic gastrinoma.
SO - Cancer 2002 Jan 15;94(2):331-43
AD - Digestive Diseases Branch, National Institute of Diabetes and Digestive
and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
20892-1804, USA.
BACKGROUND: Malignant pancreatic endocrine tumors (PETs) have a poor
prognosis and existing antitumor treatments are unsatisfactory. Recent
studies have shown somatostatin analogues to have antitumor growth
effects in patients with malignant PETs; however, to the authors'
knowledge, little information exists regarding their efficacy or effect
on survival in patients with progressive malignant gastrinoma, the most
common symptomatic malignant PET. The purpose of the current study was
to study prospectively the efficacy, safety, and effect on survival of
long-term treatment with octreotide in consecutive patients with
progressive malignant gastrinoma. METHODS: Fifteen consecutive patients
with malignant gastrinoma with progressive hepatic metastases were
studied. All patients underwent conventional imaging studies (computed
tomography scan, magnetic resonance imaging, ultrasound, and, if needed,
selective angiography) and somatostatin receptor scintigraphy prior to
treatment and at 3-6-month intervals while receiving treatment. The
patients all were treated initially with octreotide, 200 microg every 12
hours, and at last follow-up were being maintained on long-acting
release octreotide, 20-30 mg every month. Tumor size and/or number were
used to classify patient responses as either no tumor response or tumor
response (stabilization or decrease in size). Treatment response was
correlated with tumor and clinical characteristics. RESULTS: Tumors in 8
of the 15 patients studied (53%) responded at 3 months, with 47% (7 of
15 patients) demonstrating tumor stabilization and 6% (1 of 15 patients)
demonstrating a decrease in tumor size. The mean duration of response
was 25.0+/-6.1 months (range, 5.5-54.1 months). Six of the eight
responders were continuing to respond at the time of last follow-up.
Tumor response did not correlate with any clinical parameter (e.g.,
tumor extent, fasting gastrin, or acid secretory rates). However,
slow-growing tumors were more likely to respond prior to treatment (86%
vs. 0%) (P < 0.0014). During follow-up (range, 4-8 years), 25% of the
responders died compared with 71% of the nonresponders, a difference
that approached statistical significance (P = 0.10). Two patients (13%)
developed serious side effects that required the withdrawal of
octreotide. CONCLUSIONS: Octreotide is an effective antitumor treatment
in patients with progressive malignant gastrinoma. In approximately 50%
of these patients octreotide has an antigrowth effect; treatment is
associated with a low incidence of serious side effects compared with
other antitumor treatments commonly used and, in contrast to many
studies, the growth response is long-lasting. The results of the current
study suggest that octreotide treatment should replace chemotherapy as
the standard treatment for these patients, especially those patients
with slow-growing tumors. Additional studies involving larger numbers of
patients will be needed to determine a convincing effect on survival.
3
UI - 11884763
AU - Saddig C; Bender R; Starke AA
TI -
A new classification plot for the C-peptide suppression test.
SO - JOP 2002 Jan;3(1):16-25
AD - Department of Metabolic Diseases and Nutrition,
Heinrich-Heine-University of Duesseldorf, Duesseldorf, Germany.
CONTEXT AND OBJECTIVE: To evaluate the C-peptide suppression test as a
screening test in patients with symptoms of hypoglycemia as compared to
the standard fasting test. DESIGN: Retrospective discriminant analysis
of data from C-peptide suppression tests. SETTING: Clinical study.
PATIENTS: Patients with insulinomas and patients without insulinomas but
having symptoms compatible with hypoglycemia. INTERVENTIONS: The results
from C-peptide suppression tests of 26 patients with insulinomas and 100
patients without insulinomas were compared. MAIN OUTCOME MEASURES: A
classification plot which introduces two discriminant parameters for the
C-peptide suppression test: the ratio of [blood glucose]/[C-peptide] at
the lowest C-peptide concentration and mean glycemia during insulin
infusion. RESULTS: In patients with insulinomas, minimal serum C-peptide
levels were higher (1.81+/- 0.87 ng/mL; median 1.83 ng/mL; maximal
suppression 37 +/- 24% of basal C-peptide levels) as compared to
patients without insulinoma (0.40 +/- 0.15 ng/mL; median 0.30 ng/mL;
maximal suppression of 75 +/- 9%; P<0.001). Mean glycemia during the
test was lower in patients with insulinomas (30.8 +/- 3.3 vs. 47.5 +/-
8.3 mg/dL; P<0.001) as was the [blood glucose]/[C-peptide] ratio (21.9
+/- 14.6 vs. 139.2 +/- 43.8; P<0.001). Discriminant analysis revealed a
specificity of 96% to rule out the diagnosis of 'insulinoma' at a 1%
probability threshold with a sensitivity of 100%. CONCLUSIONS: We
developed a new classification plot for the C-peptide suppression test
in order to accurately identify those patients whose symptoms of
hypoglycemia are not due to endogenous hyperinsulinemia/insulinomas.
Thus, the need for fasting tests and hospitalization costs can be
reduced.
4
UI - 10354869
AU - Hes FJ; Feldberg MA
TI -
Von Hippel-Lindau disease: strategies in early detection (renal-,
adrenal-, pancreatic masses).
SO - Eur Radiol 1999;9(4):598-610
AD - Department of Internal Medicine, University Hospital Utrecht, The
Netherlands.
Von Hippel-Lindau disease (VHL) is a hereditary syndrome characterized
by a predisposition for bilateral and multicentric retinal angiomas,
hemangioblastomas in the central nervous system (CNS), renal cell
carcinomas, pheochromocytomas, islet cell tumors of the pancreas, and
endolymphatic sac tumors, as well as cysts in the kidney, pancreas, and
epididymis. This review focuses on developments in imaging of renal,
adrenal, and pancreatic masses in VHL. Radiology still has a central
place in managing of VHL. Radiologists should therefore be aware of the
importances of MRI, CT, and US compared with other radiodiagnostic tools
for these three organs. Since a conservative approach to the treatment
of VHL lesions is now becoming more widely accepted, ongoing follow-up
by careful radiological screening with US, and especially with MRI, will
play a central role in managing the disease. We also give an overview of
recent advances in the molecular biology of VHL, because the combination
of imaging with (presymptomatic) DNA analysis has made early detection
and screening of lesions possible and led to a reduction in morbidity
and mortality.
5
UI - 10454725
AU - Jinnai K; Sugio T; Mitani M; Hashimoto K; Takahashi K
TI -
Elongation of (CTG)n repeats in myotonic dystrophy protein kinase gene
in tumors associated with myotonic dystrophy patients.
SO - Muscle Nerve 1999 Sep;22(9):1271-4
AD - Department of Neurology, National Sanatorium Hyogo-Chuo Hospital, 1314,
Ohara, Sanda 669-1592, Japan.
Length of (CTG)n triplet repeats in myotonic dystrophy protein kinase
gene (DMPK) was estimated in tumors, normal tissues of the same organs,
muscles, and leukocytes from three myotonic dystrophy (DM) patients and
a non-DM patient. Using cDNA 25 as a probe, a Southern blot analysis of
EcoRI- and BglI-digested DNA from these tissues demonstrated the longest
expansion of the repeats in the tumors of DM patients. In all tissues
from a non-DM patient, the repeat length was confirmed to be stable by
PCR analysis. Our data suggest that expanded (CTG)n repeat in tumor
tissues may have increased the instability. This study emphasizes the
importance of a long-term prospective study on the incidence of tumors
in DM to clarify the pathological interrelation between the two
entities. Copyright 1999 John Wiley & Sons, Inc.
6
UI - 11566091
AU - Chatziioannou A; Kehagias D; Mourikis D; Antoniou A; Limouris G; Kaponis
TI -
A; Kavatzas N; Tseleni S; Vlachos L
Imaging and localization of pancreatic insulinomas.
SO - Clin Imaging 2001 Jul-Aug;25(4):275-83
AD - Department of Radiology, Areteion Hospital, University of Athens, 76
Vas. Sofias Street, Athens 11528, Greece.
For pancreatic insulinomas, the treatment of choice is surgical
excision, which when successful is curative. Intraoperative palpation
combined with ultrasonography theoretically depict almost all tumors,
however the accuracy of palpation is improved by the preoperative
localization. All recent advances in imaging have improved the
likelihood for curative surgical resection. Our purpose is to
demonstrate the characteristics of all modalities, which may be used in
the preoperative localization algorithm.
7
UI - 11836542
AU - Dal Coleto CC; de Mello AP; Piquero-Casals J; Lima FR; Vilela MA;
TI -
Festa-Neto C; Sanches JA Jr
Necrolytic migratory erythema associated with glucagonoma syndrome: a
case report.
SO - Rev Hosp Clin Fac Med Sao Paulo 2001 Nov-Dec;56(6):183-8
AD - Department of Dermatology, Hospital das Clinicas, Faculty of Medicine,
University of Sao Paulo, Brazil.
Necrolytic migratory erythema is a rare skin condition that consists of
migrating areas of erythema with blisters that heal with
hyperpigmentation. It usually occurs in patients with an alpha islet
cell tumor of the pancreas-or glucagonoma-and when associated with
glucose intolerance, anemia, hyperglucagonemia, and weight loss defines
the glucagonoma syndrome. We describe a 52-year-old female patient with
necrolytic migratory erythema associated with glucagonoma syndrome who
had metastatic disease at presentation and passed away one week after
her admission. The autopsy showed a tumor in the body of the pancreas,
which was diagnosed as a neuroendocrine tumor and confirmed by
immunohistochemistry. The diagnosis of necrolytic migratory erythema is
a matter of great importance, since it might be an auxiliary tool for
the early detection of glucagonoma.
8
UI - 11941895
AU - Povoski SP; Zaman SA; Ducatman BS; McFadden DW
TI -
Dermatitis, glossitis, stomatitis, cheilitis, anemia and weight loss: a
classic presentation of pancreatic glucagonoma.
SO - W V Med J 2002 Jan-Feb;98(1):12-4
AD - Division of Surgical Oncology, Department of Surgery, Arthur G. James
Cancer Hospital and Richard J. Solove Research Institute, Ohio State
University, Columbus, USA.
Glucagonomas are rare tumors. They are predominantly located in the body
or tail of the pancreas and display a constellation of signs and
symptoms referred to as glucagonoma syndrome. The term necrolytic
migratory erythema is used to characterize the distinctive rash
associated with this syndrome. This report describes a classic
presentation consisting of dermatitis, glossitis, stomatitis, angular
cheilitis, anemia, and weight loss that was associated with the finding
of a pancreatic mass and a markedly elevated plasma glucagon level.
After pancreatic resection, the patient had complete resolution of the
rash and normalization of plasma glucagon.
9
UI - 11881729
AU - Ohike N; Morohoshi T
TI -
Immunohistochemical analysis of cyclooxygenase (COX)-2 expression in
pancreatic endocrine tumors: association with tumor progression and
proliferation.
SO - Pathol Int 2001 Oct;51(10):770-7
AD - First Department of Pathology, Showa University School of Medicine,
Tokyo, Japan. ohike@med.showa-u.ac.jp
An immunohistochemical study of cyclooxygenase (COX)-2 expression in
pancreatic endocrine tumors (PET) was carried out, and the expression of
COX-2 was compared with pathological features, the expression of several
markers (hormones, vascular endothelial growth factor, single-stranded
DNA, and the Ki-67 labeling index [LI]). Twenty PET, including 10
metastasizing cases (tumor size: 3-8 cm) and 10 non-metastasizing cases
(tumor size: 0.3-8 cm) were studied. Tumors with a high level of COX-2
expression were placed in the H group, and the remaining tumors were
placed in the L group. The H group was comprised of 13 tumors: all 10 of
the metastasizing cases and three of the non-metastasizing cases. There
were significant differences in tumor size between the two groups (H
group 46.5 mm; L group 0.9 mm). There were significant differences in
the presence of the following histological criteria for malignancy:
pleomorphism (H group 13/13; L group 1/7), mitotic activity (H group
2.9; L group 0) and/or angioinvasion (H group 13/13; L group 1/7); and
there were also significant differences in the number of cases that
expressed ectopic hormones (gastrin, vasoactive intestinal peptide,
serotonin and calcitonin; H group 12/13; L group 2/7) and in the Ki-67
LI (H group 8.3%; L group 0.4%). The distribution of COX-2-positive
cells tended to be similar to the distribution of Ki-67-positive cells.
Our data show that COX-2 is frequently upregulated in malignant PET and
that there is a close relationship between COX-2 expression and tumor
progression/proliferative activity.
10
UI - 11903191
AU - Ramsay D; Gibson P; Edmunds S; Mendelson R
TI -
Pancreatic islet cell tumours presenting as recurrent acute
pancreatitis: imaging features in three cases.
SO - Australas Radiol 2001 Nov;45(4):520-3
AD - Department of Interventional and Diagnostic Radiology, The Royal Perth
Hospital, Western Australia.
We present three cases of recurrent pancreatitis that occurred in
patients with small islet cell tumours of the pancreas which were
obstructing the main pancreatic duct. This is a very uncommon
presentation of pancreatic islet cell tumours. The radiological findings
in these cases are shown and the implications for imaging of
'idiopathic' relapsing pancreatitis are discussed.
11
UI - 11785413
AU - Kostiuk TS
TI -
[Observation of pancreatic incidentaloma]
SO - Klin Khir 2001 Sep;(9):62-3
12
UI - 11923783
AU - Gress FG; Barawi M; Kim D; Grendell JH
TI -
Preoperative localization of a neuroendocrine tumor of the pancreas with
EUS-guided fine needle tattooing.
SO - Gastrointest Endosc 2002 Apr;55(4):594-7
AD - Division of Gastroenterology, Hepatology and Nutrition, Department of
Surgery, Winthrop University Hospital, Mineola, New York 11501, USA.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
